We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Syri Ltd has been fined £51,000 and ordered to pay costs of £104,898 by Aylesbury Crown Court.
A reflection by Dr June Raine, Chief Executive of the Medicines and Healthcare products Regulatory Agency
The vaccine has been approved after meeting the required safety, quality and effectiveness standards.
The MHRA has launched a public consultation on a set of proposals to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies.
Significant clarification of the life-changing EAMS scheme to be introduced into law.
People are encouraged to contribute their views on far-reaching proposed revisions to the clinical trial legislation in the UK
A statement from Dame June Raine DBE on being recognised in the 2022 New Year Honours List
This new combination treatment is for people with mild to moderate COVID-19 who are at high risk of developing severe COVID-19
The Medicines and Healthcare products Regulatory Agency has today issued a recall asking patients to return affected products.
A new paediatric formulation of the Pfizer BioNTech COVID-19 vaccine has been approved for children aged 5 to 11 after meeting the required safety, quality and effectiveness standards.
This new guidance follows consultation with stakeholders from the pharmaceutical industry, academic research, trade associations, patient organisations/charities, healthcare providers and regulatory organisations.
A statement on the temporary waiver of 15-minute observation period after COVID-19 mRNA vaccines
This monoclonal antibody – the second to be authorised by the Medicines and Healthcare products Regulatory Agency – is for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
As a precaution, companies are recalling some batches of irbesartan medicines due to presence of a chemical substance (AZBT) in an amount over the limit permitted for this product. Patients taking irbesartan medicines should…
A statement from Dr June Raine on expansion of the COVID-19 vaccination booster programme.
Our safety monitoring to date shows that COVID-19 vaccines continue to have a positive safety profile for the majority of people.
The chance for adults and children suffering from life-threatening allergic reactions to get life-saving shots of adrenaline in public places, such as restaurants and entertainment venues, has come a step closer as a result …
The labelling states an incorrect maximum daily dose for 12-15-year olds. The MHRA, who issued the recall, says that that the risk to patients is very low.
The antiviral was found to be safe and effective following a stringent review of the available evidence.
Dr Laura Squire OBE has begun her role as the Medicines and Healthcare products Regulatory Agency’s (MHRA) Chief Healthcare Quality and Access Officer
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).